the scientific seminar series is designed to reach the microbiology community to disseminate knowledge across its professional networks. the events are designed as a regularly repeated series of short (typically 1–2 hour) online meetings.
the journal of medical microbiology (jmm) monthly seminar series is designed to showcase high-quality and timely research from the journal’s key authors. jmm welcomes everything from laboratory research to clinical trials, including bacteriology, virology, mycology, and parasitology. the jmm seminars will reflect this same comprehensive scientific content.
sign up to attend this series of seminars via the 'registration' tab. instructions on how to join the zoom session will be sent ahead of each seminar.
please note all times listed on the programme are in bst (uk time).
* by completing and submitting this form, you understand, and hereby consent that the personal data provided by you in this form will be collected, processed and used by the 英格兰vs美国谁会赢？ to send you any communication relating to the event. you understand and hereby consent that the personal data provided by you in this form will be collected, processed and used by the 英格兰vs美国谁会赢？ for the following additional purposes, but only if you tick the relevant box above. the 英格兰vs美国谁会赢？ is the data controller for the purpose of data protection legislation. the 英格兰vs美国谁会赢？ is a charity registered in england and wales (charity number 264017), a charity registered in scotland (charity number sc039250) and a company limited by guarantee, registered in england (company number 1039582).
sign up to attend this series of seminars below. you will receive an email with information about each upcoming presentation, including joining instructions, a zoom link, and any other relevant information, two days before each seminar. a second reminder email will be sent one hour before each seminar. unfortunately, if you have signed up less than one hour before the seminar you will not be able to attend until the next seminar in the series.
please note all times listed on the programme are in gmt (uk time).
all seminars will be run via zoom, a link for which will be sent to you via email prior to the meeting. please ensure you have updated to the latest version of the zoom desktop or mobile application (version 5.3 or higher is recommended).
kim hardie is professor in bacterial pathogenesis within the school of life sciences at the university of nottingham, uk, and co-leads the division of infection, immunity and microbes. she is also co-investigator in the national biofilm innovation centre and co-director for the wellcome trust doctoral training programme on antimicrobials and antimicrobial resistance that is held jointly with the university of birmingham. kim studied at the universities of leicester and cambridge, uk, before undertaking postdoctoral research at the university of victoria, canada, and institut pasteur, france. she joined the jmm editorial board in 2011 and is currently senior editor for the pathogenicity, virulence and host response section. her research group studies how proteins are secreted and how bacteria regulate these proteins. the work specifically aims to understand the fitness burden of producing signalling molecules that are used by bacteria to communicate with each other, and how this impacts on pathogenicity. to do this, kim’s research group have been investigating how bacteria form coordinated communities on surfaces (biofilms) including skin. state-of-the-art multidisciplinary approaches are combined with realistic infection models to investigate how antimicrobials penetrate complex biofilm structures. her aim is to discover novel antimicrobials, or more effective combination therapies.
kim communicates science as broadly as possible. her portfolio of outreach activities includes the royal society summer exhibition (2019, 2020), media interviews (tv and radio), science festivals, wonder, bespoke school/nhs outreach, and learned society governance roles (royal society of biology and 英格兰vs美国谁会赢？ ).
professor kalai mathee, who hails from malaysia, is the first florida international university (fiu) faculty member inducted as a fellow of the american academy of microbiology for her original contributions to advance science and microbiology in 2020. of the two malaysians ever inducted, she is the second and the first woman. the academy is the honorific leadership group within the american society for microbiology, one of the world's oldest and largest life science societies. she also serves as editor-in-chief along with norman fry of public health england (uk health security agency) of the journal of medical microbiology, the first international editor in its 50-year history.
mathee joined fiu in 1999 as an assistant professor in the department of biological sciences. when fiu created the medical college, she became the first founding faculty and the founding chair of the department of molecular microbiology and infectious diseases. she rose to the rank of professor in 2010. in 2011, she founded [email protected] frost at fiu that uses artwork to addresses civil rights. she founded the fiu global health conference in 2011 and the global health consortium in 2014. in 2011, she was awarded the president's council worlds ahead faculty award, the highest honor at fiu. in 2014, she was one of the inaugural recipients of the new england biolabs passion in science award for exemplary scientific mentorship and advocacy.
she has mentored 140+ individuals, from professors to middle-school students. along with her mentees, she has published more than 130 articles and several book chapters in the fields of alginate gene regulation, antimicrobial resistance, gut and lung metagenome and microbiome, alternate therapeutics, forensic science, comparative genomics and bioinformatics. she has five patents to her credit.
mathee received her phd in molecular microbiology and immunology at the university of tennessee, memphis, in 1992. in 2018, she obtained her master's in public health, majoring in health policy and management from florida international university. a native of malaysia, she received a bachelor of science in genetics (1984) and a master of science (1986) in microbial genetics from the university of malaya.
rikke meyer has an msc and phd in microbiology and is an associate professor at the interdisciplinary nanoscience center at aarhus university, denmark. she is leading an interdisciplinary research group that combines microbiology and nanotechnology to understand how bacteria adhere to surfaces and form biofilms, and how biofilms can be prevented or treated through innovations in nanoscience, chemistry and biotechnology.
for example, her research has shown that bacteria use extracellular dna to adhere to surfaces with a wide range of properties. dna is a key component of the biofilm matrix in biofilms from freshwater to industrial systems and for clinically relevant pathogens. her work on host-pathogen interactions by staphylococcus epidermidis has provided a new understanding of how biomaterials can facilitate bacterial attachment by steering the conformation of host proteins that adsorb to the material surface.
she has collaborated with many research groups and private companies to develop antifouling or antimicrobial solutions through nanoscale coatings, enzymes, nanoparticles and nanoformulation of antibiotics. fundamental and applied research projects go hand in hand in her laboratory, ensuring a short path from research to innovation.
dr salvador almagro-moreno received his bs in biology from the university of granada and phd in microbiology from the national university of ireland. subsequently, he moved to the united states as the e. e. just postdoctoral fellow at dartmouth college, usa. currently, he is an assistant professor of medicine at the university of central florida in orlando, usa.
the moreno lab focuses on the emergence and evolution of bacterial pathogens. their primary research interests include elucidating the molecular strategies that bacterial pathogens develop for host colonisation, virulence regulation and dispersal from the host. furthermore, they are interested in connecting ecosystems with manmade environmental perturbations (e.g. climate change, pollution) to determine their pathogenic potential and transmission. his research program focuses on several pathogenic members of the vibrionaceae, a family of aquatic bacteria, as model systems. in addition, investigations emphasize the intestinal pathogen vibrio cholerae, which represents a paradigm of infectious disease agents, and vibrio vulnificus, a poorly understood emergent zoonotic pathogen, source of fulminant septicemia. his research approach strives to be holistic and multidisciplinary; what we call “from bays to bases.” it encompasses molecular biology, genomics, ecology, and pathogenesis. he believes that by understanding pathogen evolution and ecology, to ultimately gain the knowledge that will allow forecasting the traits of emergent virulent strains, predict the sources of outbreaks, and designing reliable treatments against bacterial threats.
research in the moreno lab has been funded by the us national science foundation, the national institutes of health, the united states food and drug administration, and the binational science foundation. dr almagro-moreno has received numerous awards and honors, including the national science foundation career award and the scialog fellowship on mitigating zoonotic threats. he recently became one of the burroughs wellcome fund investigators in the pathogenesis of infectious disease.
to learn more about the moreno lab, please visit www.vibriocholerae.org.
dr. arnoud van vliet is a senior lecturer in microbiology at the school of veterinary medicine of the university of surrey, uk. he received his ph.d. in infectious diseases from the university of utrecht in 1995 and has led research groups at the erasmus mc rotterdam in the netherlands and the institute of food research, norwich, uk. his research focuses on zoonotic bacterial pathogens such as campylobacter, listeria, escherichia coli, and salmonella. while he trained as an experimental scientist, he moved into the area of genomics/bioinformatics, intending to use genome sequencing and analysis technologies to understand better bacterial virulence, biology, epidemiology, and antimicrobial resistance. one of his goals is to make bioinformatics/genomics more accessible and user-friendly to novice users. he is currently senior editor of the molecular and microbial epidemiology section of jmm and has been an editor of microbiology journals since 2003.
dr. leal has a broad background in microbiology, immunology, molecular biology and medicine with residency training in pathology and subspecialty fellowship training in medical microbiology. he received his md/phd training in the medical scientist training program (mstp) at case western reserve university, pathology residency training at the university of north carolina in chapel hill, and microbiology fellowship training at the cleveland clinic. he is certified by the american board of pathology in clinical pathology and medical microbiology and is a diplomate of the american board of medical microbiology. he has a special clinical and research interest in medical mycology and has been at the forefront of covid-19 diagnostic response and the study of covid-associated 2° mold infections.
norman is a consultant clinical scientist and laboratory surveillance lead for vaccine preventable bacteria at the uk’s health security agency (ukhsa), colindale, london, uk. the ukhsa brings together the health protection functions of public health england and national health service test and trace, including the joint biosecurity centre. norman is also head of the vaccine preventable bacteria section which includes the national reference laboratories for streptococcus pneumoniae, haemophilus influenzae, bordetella pertussis and diphtheria. his laboratory also hosts the world health organisation collaborating centre (who cc) for streptococcus pneumoniae and haemophilus influenzae (co-heads: norman fry & david litt) and the who cc for diphtheria and streptococcal infections (head, prof androulla efstratiou). norman is also co-editor-in-chief (with prof kalai mathee) for one of the 英格兰vs美国谁会赢？ journals, the journal of medical microbiology.
norman completed a bsc (hons) in microbiology and virology from the university of warwick in 1984, and was awarded a phd on legionella in 1992 whilst at colindale. from 1992-1995 he moved to the usa to pursue a post-doctoral fellowship exploring microbial populations in the deep subsurface at the university of illinois and northwestern university, with field trips to the pacific northwest national laboratory, richland, washington state to filter many litres of groundwater. he returned to colindale, public health microbiology and legionella in 1996, then moved into working on the bacteria causing vaccine preventable diseases.
tim inglis is a uk-trained medical microbiologist, who migrated via singapore to australia, and deputy editor-in-chief of journal of medical microbiology. his work on emerging infectious diseases in western australia has emphasised capability building in regional, rural and remote locations where pathology support is lacking. currently, much of his time is taken up on covid laboratory activities, and if it weren’t for the pandemic, he would be working flat out on new methods for rapid diagnosis of systemic, drug-resistant infections in regional australia. in his spare time, he enjoys trail running and looking after a smallholding.
dr lynn silver received her phd in molecular and microbiology at tufts university in 1975 and did postdoctoral work at the university of geneva and nih. in 1982, she joined merck research laboratories, where she conducted research and supervised groups in discovery efforts for new antibacterials in both natural products and chemical collections. she oversaw various programs involving inhibitors of dna and cell wall synthesis, participated in the discovery of the first published inhibitors of lpxc and the novel antibiotic platensimycin (fabf inhibitor). her group also supported many chemistry efforts toward improving classic antibiotics, such as macrolides, glycopeptides and carbapenems, to overcome resistance. she was a member of several drug-development project teams including that of the carbapenem invanzò. as a member of an in-licensing committee, she was involved in due diligence of academic and biotech projects and compounds.
after taking early retirement from merck, she became an independent consultant in antibacterial discovery and pre-clinical development in 2004. throughout her career, she has authored significant research papers and reviews in the field of bacterial genetics, physiology, and biochemistry, as well as the challenges to discovery of antibacterial agents. currently, she has been participating in scientific advisory boards of several groups funding antibiotic discovery and development.
biofilms: bacterial fortresses that cause chronic infections
cholera: the forgotten pandemic
the wondrous world of pathogen genomics and molecular epidemiology: dos, don'ts and other stories
|14:00–15:00||tackling covid-19 in the clinical and mycology research lab
dr sixto m. leal jr. (university of alabama at birmingham, usa)
|14:00–15:00||how to improve your manuscript writing skills by dissecting its anatomy
professor kalai mathee (florida international university, miami, usa)
|14:00–15:00||diphtheria: the strangling angel
dr norman fry (uk health security agency, uk)
|14:00–15:00||covid-19: a lesson in pandemic preparedness
dr tim inglis (university of western australia, crawley, australia)
|14:00–15:00||sars-cov-2 vaccines and variants: myths, misconceptions and facts
professor kalai mathee (florida international university, miami, usa)
|14:00–15:00||antibiotics: challenges of antimicrobial discovery revisited
dr lynn silver (independent public health expert)